Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EC-MPS · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| EC-MPS | DRUG | - |
Inclusion Criteria: Patients who were participating in the core study CERL080A2401 and have successfully completed the first 12 months of the core study Exclusion Criteria: Patients who did not complete the 12-month core study CERL080A2401 Other protocol-defined inclusion/exclusion criteria may ...
EC-MPS, or enteric-coated mycophenolate sodium, is an investigational small molecule being studied in heart transplant recipients. It is intended for patients who successfully completed the 12-month treatment period of the core study in de novo heart recipients and were interested in continued treatment with EC-MPS.
EC-MPS is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is a small molecule therapeutic candidate in the cardiovascular therapeutic area.
EC-MPS is in Phase 3 clinical development. It has completed one Phase 3 trial, and it remains an investigational drug that has not been approved for any use. The completed trial was an uncontrolled, randomized study in heart transplant recipients.
EC-MPS has one completed Phase 3 clinical trial registered under NCT00238446, titled "Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients." The trial enrolled adults aged 18 years and older of all sexes, and it was not double-blinded.
Yes, EC-MPS is the same as enteric-coated mycophenolate sodium. The drug is commonly referred to by its abbreviation EC-MPS, and the full name appears in the clinical trial title. It is a small molecule being studied for use in heart transplant recipients.